Keytruda Global Market Report 2024

Keytruda, also known as pembrolizumab, is a monoclonal antibody medication utilized in cancer treatment. It falls under the category of immune checkpoint inhibitors, working by targeting and blocking the PD-1 (programmed cell death protein 1) protein in immune cells. This action assists the immune system in recognizing and attacking cancer cells effectively.

Keytruda is primarily used in treating various cancer types, including melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, and urothelial carcinoma. Melanoma, specifically, is a type of skin cancer that originates in melanocytes, the cells responsible for producing melanin, the pigment giving skin its color. The medication is available through different payer types such as commercial, Medicare, and Medicaid, and distributed through various channels such as hospital pharmacies and specialty pharmacies.

The keytruda market research report is one of a series of new reports that provides keytruda market statistics, including keytruda industry global market size, regional shares, competitors with a keytruda market share, detailed keytruda market segments, market trends and opportunities, and any further data you may need to thrive in the keytruda industry. This keytruda market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The keytruda market size has grown strongly in recent years. It will grow from $19.71 billion in 2023 to $21.6 billion in 2024 at a compound annual growth rate (CAGR) of 9.6%. The growth observed in the historic period can be attributed to several factors, including improved patient outcomes, increased adoption of immunotherapy in cancer treatment, ongoing research and development efforts, enhanced patient compliance with treatments, and increased adoption of Keytruda (pembrolizumab) as a medication for cancer therapy.

The keytruda market size is expected to see strong growth in the next few years. It will grow to $31.52 billion in 2028 at a compound annual growth rate (CAGR) of 9.9%. The expected growth in the forecast period can be attributed to several factors, including expanding indications for Keytruda (pembrolizumab), emerging markets for cancer treatments, the increasing prevalence of cancer cases, rising healthcare expenditure globally, and the growing demand for precision medicine in oncology. Major trends anticipated during this period include a heightened demand for targeted therapies such as Keytruda, advancements in immunotherapy approaches, innovations in diagnostic technologies for cancer detection and monitoring, a surge in demand for effective cancer treatments, and ongoing advancements in cancer research.

The growth of the Keytruda market is expected to be propelled by the increasing prevalence of cancer. Cancer, a complex group of diseases characterized by abnormal cell growth and spread, is influenced by genetic, lifestyle, environmental, and hormonal factors. Keytruda (pembrolizumab) plays a crucial role in cancer treatment by leveraging the body's immune system to combat cancer cells more effectively. This represents a significant advancement in cancer treatment by harnessing immune system capabilities to target and attack cancer cells, offering new hope to patients with advanced or metastatic cancers. For example, according to the National Library of Medicine, the global cancer burden is projected to reach 28.4 million cases in 2040, marking a 47% increase from 2020. Thus, the rising prevalence of cancer is a driving force behind the Keytruda market.

Leading companies in the Keytruda market are focused on developing innovative products such as pembrolizumab to expand treatment options. Pembrolizumab, a monoclonal antibody medication belonging to immune checkpoint inhibitors, is marketed under the brand name Keytruda. It targets and inhibits a protein called PD-1 (programmed cell death protein 1) on immune cells known as T cells. For instance, in November 2023, Merck, a US-based pharmaceutical company, launched KEYTRUDA (pembrolizumab) in combination with fluoropyrimidine- and platinum-containing chemotherapy approved by the Food and Drug Administration (FDA). This combination therapy has shown significant improvements in overall survival and progression-free survival compared to chemotherapy alone, presenting a promising advancement in gastric cancer treatment. Clinical trials have demonstrated enhancements in overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) compared to standalone chemotherapy.

In May 2024, CytomX Therapeutics, a US-based biotechnology company, partnered with Merck to assess CX-801 with KEYTRUDA (pembrolizumab) in patients with advanced metastatic solid tumors. This collaboration aims to evaluate the safety, tolerability, and preliminary efficacy of CX-801 in combination with KEYTRUDA for advanced metastatic solid tumors. Merck, a US-based company, offers Keytruda as part of its pharmaceutical portfolio.

Major companies operating in the keytruda market are Pfizer Inc., Johnson & Johnson Services Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis AG, AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Chugai Pharmaceutical Co. Ltd., BioNTech AG, Organon Co., Ono Pharmaceutical Co. Ltd., Samsung Bioepis Co. Ltd., Fate Therapeutics Inc., Merck Sharp & Dohme Corp., KinBio, Schering-Plough AB, LGM Pharma LLC, Gritstone Bio Inc.

North America was the largest region in the keytruda market in 2023. The regions covered in the keytruda market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the keytruda market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The keytruda market consists of sales of immunotherapy, combination therapies, clinical trials, and personalized medicine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.